HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
Ying Wan, Speaker at Vaccine Research Conference
Merck & Co., United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals

Abstract:

Physical appearance (PA) is an attribute indicating the quality of parenteral pharmaceuticals. It is routinely evaluated during release and stability testing and included in regulatory filings. PA assessment of liquids involves three tests: visible particulates, clarity, and color. For each test, compendial general method chapters are available requiring minimal modification. This allows for a platform PA method approach, streamlining method readiness for new test articles. However, selecting the appropriate method is challenging, as no method suits all test articles, and pharmacopeias do not specify suitable condition(s) for each method. Improper method selection can lead to inappropriate specification setting and unreliable results. The need for guidance is especially urgent for vaccines, which often exhibit a wide range of PA attributes due to complex delivery systems and adjuvants that boost immunogenicity.

This presentation addresses this challenge by explaining method suitability and presenting a decision table for PA method selection based on the appearance properties of pharmaceuticals. A case study involving a yellow-turbid vaccine adjuvant is presented to demonstrate the practical application of the decision table. When color and turbidity make visual comparison to reference liquids difficult, instrumental clarity and visual qualitative methods are suitable options. The manuscript provides valuable insights on PA method selection and setting specifications for new parenteral pharmaceuticals. Furthermore, the decision table enables platform methods for test articles sharing similar appearance properties, eliminating the need for individual methods, reducing document preparation time for method and verification protocol, and enhancing the consistency and efficiency of GMP testing for PA.

Biography:

Dr. Ying Wan received her PhD from the University of Missouri and completed postdoctoral training at the Vaccine Analytics and Formulation Center, University of Kansas, under Drs. David Volkin and Sangeeta Joshi. She joined Merck in 2020 and is an Associate Principal Scientist in Vaccines Analytical R&D GxP Laboratories. Dr. Wan has published in journals such as PNAS and AAPS and spoke at the PDA Annual Meeting. She has extensive expertise in vaccine analytics, formulation, and GMP testing for various vaccine candidates and is a subject matter expert in compendial methods including visible particulates, color, clarity, volume of fill, and container closure integrity methods.

Watsapp